Titan Medical Inc. (TSX: TMD, Nasdaq: TMDI) has announced it has cured its bid price deficiency and regained compliance with Nasdaq listing requirements as of December 24, 2020. The company focuses on developing robotic-assisted technologies for single-access surgery, particularly through its Enos system, which integrates advanced imaging and ergonomic design to enhance surgical procedures. Titan retains worldwide rights for commercializing certain technologies that have been licensed to Medtronic, aiming to set new standards in gynecologic surgery.
Titan Medical (TMDI) will present at the LD 500 investor conference on September 2, 2020, at 11:20 AM ET. David McNally, President and CEO, will address a live virtual audience through a webcast. The LD 500 conference runs from September 1-4, 2020. Titan Medical develops innovative single-port robotic surgical technologies aimed at enhancing minimally invasive surgery. Interested individuals can register for the conference and view Titan’s profile online.